The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic

Molecular Pharmaceutics

Volumn 6, Issue 3, 2009, Pages 659-668

  Davis, Mark E ^a  

^a California Institute of Technology   (United States)

Author keywords

CALAA 01; Clinical trial; siRNA; Targeted delivery; Targeted nanoparticle

Indexed keywords

CALAA 01; CYCLODEXTRIN; LIGAND; MACROGOL; NANOPARTICLE; POLYMER; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

CANCER CELL; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG TARGETING; EXPERIMENTAL STUDY; HUMAN; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; UPREGULATION;

ANIMALS; CELLULOSE; CYCLODEXTRINS; HUMANS; MICE; NANOPARTICLES; NANOTECHNOLOGY; POLYETHYLENE GLYCOLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFERRIN;

EID: 67249128859     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900015y     Document Type: Review

References (42)

1. Edbrooke, M.; Clarke, N. RNAi therapeutics: addressing targets. Eur. Pharm. Rev. 2008, 4, 11-17.
2. Davis, M. E. Non-Viral Gene Delivery Systems. Curr. Opin. Biotechnol. 2003, 13, 128-131.
3. Hwang, S. J.; Davis, M. E. Cationic Polymers for Gene Delivery: Designs for Overcoming Barriers to Systemic Administration. Curr. Opin. Mol. Ther. 2001, 3, 183-191. (Pubitemid 32390247)
4. Davis, M. E.; Pun, S. H.; Bellocq, N. C.; Reineke, T. M.; Popielarski, S. R.; Mishra, S.; Heidel, J. D. Self-Assembling Nucleic Acid Delivery Vehicles via Linear, Water-Soluble, Cyclodextrin-Containing Polymers. Curr. Med. Chem. 2004, 11, 179-197. (Pubitemid 38128844)
5. Davis, M. E.; Brewster, M. E. Cyclodextrin-based pharmaceutics: Past, present, future. Nat. Rev. Drug Discovery. 2004, 3, 1023-1035. (Pubitemid 39642365)
6. Gonzalez, H.; Hwang, S. J.; Davis, M. E. A New Class of Polymers for the Delivery of Macromolecular Therapeutics. Bioconjugate Chem. 1999, 10, 1068-1074.
7. Hwang, S. J.; Bellocq, N. C.; Davis, M. E. Effects of Structure of β-Cyclodextrin-Containing Polymers on Gene Delivery. Bioconjugate Chem. 2001, 12, 280-290. (Pubitemid 32235481)
8. Reineke, T. M.; Davis, M. E. Structural Effects of Carbohydrate- Containing Polycations on Gene Delivery. Part 1: Carbohydrate Size and Its Distance from Charge Centers. Bioconjugate Chem. 2003, 14, 247-254. (Pubitemid 36169039)
9. Reineke, T. M.; Davis, M. E. Structural Effects of Carbohydrate- Containing Polycations on Gene Delivery. Part 2: Charge Center Types. Bioconjugate Chem. 2003, 14, 255-261. (Pubitemid 36169040)
10. Popielarski, S. R.; Mishra, S.; Davis, M. E. Structural Effects of Carbohydrate-Containing Polycations on Gene Delivery. 3. Cyclodextrin Type and Functionalization. Bioconjugate Chem. 2003, 14, 672-678. (Pubitemid 36597379)
11. Davis, M. E.; Bellocq, N. C. Cyclodextrin-Containing Polymers for Gene Delivery. J. Inclusion Phenom. Macrocyclic Chem. 2003, 44, 17-22. (Pubitemid 38075657)
12. Pun, S. H.; Davis, M. E. Cyclodextrin-Containing Polymers for Gene Delivery. In Polymeric Gene Delivery: Principles and Applications; Amiji, M. M., Ed.; CRC Press: Boca Raton, FL, 2004; pp 187-210.
13. Behr, J. P. The proton sponge: A trick to enter cells that viruses did not exploit. Chimia 1997, 51, 34-36. (Pubitemid 127033737)
14. Putnam, D.; Gentry, C.; Pack, D.; Langer, R. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 1200-1205. (Pubitemid 32121210)
15. Midoux, P.; Monsigny, M. Efficient Gene Transfer by Histidylated Polylysine/pDNA Complexes. Bioconjugate Chem. 1999, 10, 406-411. (Pubitemid 29243322)
16. Hwang, S. Rational design of a new class of cyclodextrin-containing polymers for gene delivery. Ph.D. Thesis in Chemical Engineering, California Institute of Technology, Pasadena, CA, 2001.
17. Kulkarni, R. P.; Mishra, S.; Fraser, S. E.; Davis, M. E. Single Cell Kinetics of Intracellular, Non-Viral, Nucleic Acid Delivery Vehicle Acidification and Trafficking. Bioconjugate Chem. 2005, 16, 986-994. (Pubitemid 41026184)
18. Mishra, S.; Heidel, J. D.; Webster, P.; Davis, M. E. Imidazole End Groups on a Linear, Cyclodextrin-Containing Polycation Produce Enhanced Gene Delivery via Multiple Processes. J. Controlled Release 2006, 116, 179-191.
19. Pun, S. H.; Davis, M. E. Development of a Non-Viral Gene Delivery Vehicle for Systemic Application. Bioconjugate Chem. 2002, 13, 630-639. (Pubitemid 34527526)
20. Bartlett, D. W.; Davis, M. E. Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles. Bioconjugate Chem. 2007, 18, 456-468. (Pubitemid 46493517)
21. Mishra, S.; Webster, P.; Davis, M. E. PEGylation Significantly Affects Cellular Uptake and Intracellular Trafficking of Non-viral Gene Delivery Particles. Eur. J. Cell Biol. 2004, 83, 97-111.
22. Bellocq, N. C.; Pun, S. H.; Jensen, G. S.; Davis, M. E. Transferrin-Containing, Cyclodextrin Polymer-Based Particles for Tumor-Targeted Gene Delivery. Bioconjugate Chem. 2003, 14, 1122-1132.
23. Pun, S. H.; Tack, F.; Bellocq, N. C.; Cheng, J.; Grubbs, B. H.; Jensen, G. S.; Davis, M. E.; Brewster, M.; Janicot, M.; Janssens, B.; Floren, W.; Bakker, A. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferring-modified, cyclodextrin-based particles. Cancer Biol. Ther. 2004, 3, 641-650. (Pubitemid 41351103)
24. Bellocq, N. C.; Davis, M. E.; Engler, H.; Jensen, G. S.; Liu, A.; Machemer, T.; Maneval, D. C.; Quijano, E.; Pun, S. H.; Schluep, T.; Wen, S. Transferrin-targeted, cyclodextrin polycation-based gene vector for systemic delivery. Mol. Ther. 2003, 7, S290.
25. Bartlett, D. W.; Davis, M. E. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol. Bioeng. 2007, 97, 909-921. (Pubitemid 47051060)
26. Bartlett, D. W.; Davis, M. E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006, 34, 322-333. (Pubitemid 43160055)
27. Heidel, J. D.; Hu, S; Liu, X. F.; Triche, T. J.; Davis, M. E. Lack of Interferon Response in Animals to Naked siRNA. Nat. Biotechnol. 2004, 22, 1579-1582. (Pubitemid 40039462)
28. Judge, A. D.; Sood, V.; Shaw, J. R.; Fang, D.; McClintock, K.; MacLachlan, I. Sequence-independent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 2005, 23, 457-462. (Pubitemid 41724921)
29. Judge, A. D.; Bola, G.; Lee, A. C. H.; MacLachlan, I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 2006, 13, 494-505. (Pubitemid 43257617)
30. Hu-Lieskovan, S.; Heidel, J. D.; Bartlett, D. W.; Davis, M. E.; Triche, T. J. Sequence-specific knockdown of EWS-FLI1 by targeted, non-viral delivery of siRNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005, 65, 8984-8992.
31. Bartlett, D. W.; Su, H.; Hildebrandt, I. J.; Weber, W. A.; Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 15549-15554. (Pubitemid 47502954)
32. Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66, 6732-6740. (Pubitemid 44085631)
33. Bartlett, D. W.; Davis, M. E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 2008, 99, 975-985. (Pubitemid 351316639)
34. Heidel, J. D. Linear cyclodextrin-containing polymers and their use as delivery agents. Expert Opin. Drug Delivery 2006, 3, 641-646. (Pubitemid 44383491)
35. Heidel, J. D.; Liu, J. Y. C.; Yen, Y.; Zhou, B.; Heale, B. S. E.; Rossi, J. J.; Bartlett, D. W.; Davis, M. E. Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In Vitro and In Vivo. Clin. Cancer Res. 2007, 13, 2207-2215. (Pubitemid 46649891)
36. Cerqueira, N. M. F. S. A.; Pereira, S.; Fernandes, P. A.; Ramos, M. J. Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumor therapy. Curr. Med. Chem. 2005, 12, 1283-1294. (Pubitemid 40711424)
37. Heidel, J. D.; Yu, Z.; Liu, J. Y. C.; Rele, S. M.; Liang, Y.; Zeidan, R. K.; Kornbrust, D. J.; Davis, M. E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase sub-unit M2 siRNA. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 5715-5721. (Pubitemid 47175600)
38. Chuang, H. F.; Heidel, J. D.; Liu, J. Y. C.; Zeidan, R. K.; Liang, Y.; Rele, S.; Davis, M. E. siRNA delivery by RONDEL™ (trademark) a cyclodextrin-polymer based delivery system: from benchtop to the clinic. Abstract, AIChE meeting, 2008.
39. Davis, M. E.; Chen, Z.; Shin, D. M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discovery 2008, 7, 771-782.
40. Heath, J. R.; Davis, M. E. Nanotechnology and Cancer. Annu. Rev. Med. 2008, 59, 251-265.
41. Brahmamdam, P.; Watanabe, E.; Unsinger, J.; Chang, K. C.; Schierding, W.; Hoekzema, A. S.; Zhou, T. T.; McDonough, J. S.; Holemon, H.; Heidel, J. D.; Coopersmith, C. M.; McDunn, J. E.; Hotchkiss, R. S. Targeted delivery of siRNA to cell death proteins in sepsis. Shock, 2009. In press.
42. Alabi, C.; Choi, C. H. J.; Webster, P.; Davis, M. E. Gold nanoparticle biodistribution and subcellular localization studies: on the route towards targeted nanoparticles. Abstract, OTS meeting, 2008.